Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening: Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: healthy | Torsades de pointes | Torsades de pointe | menopause
Age: Between 21 - 100 Years
Postmenopausal women, based on the following criteria:
Age 50 years of age or older AND
History of breast, ovarian or uterine cancer
Taking hormone replacement therapy
Heart failure due to reduced ejection fraction (left ventricular ejection fraction 40%)
Family or personal history of long-QT syndrome, arrhythmias or sudden cardiac death
Concomitant use of any QT interval prolonging drug
Permanently paced ventricular rhythm
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required